It is with great pleasure that I wish you all a happy New Year.
It is finally entering the 2020s. This is the year of the Olympic and Paralympic Games Tokyo, and I hope it will be a year with full of bright topics. Looking back at 2019, Japan national rugby union team showed a remarkable performance in the Rugby World Cup and I believe many of you got enthusiastic about the exciting matches. It was really impressive that one sport won the hearts and minds of people. I would like to see such scenes everywhere in the Olympics and Paralympic Games in Tokyo too.
In 2020, we, GTS, will promote R&D and business development for the realization of "GTS3.0" which has been advocated since 2018. As part of this, GTS acquired Advanced Cell Technology and Engineering Ltd., last year, focusing on R&D with SHED (stem cell from exfoliated deciduous teeth) for regenerative medicine use, in order to accelerate growth of our cell therapy business, which is one of our three core businesses. We believe the application of SHED for therapeutic treatment is prominent, and will proceed with our business to deliver a treatment to patients at the earliest possible.
In addition, GTS will steadily implement our biosimilar business, which builds our base to conduct cell therapy and the new biologic business. Last year, we launched the second product in our biosimilar business. We will continue to work to deliver our high-quality biosimilar products to patients and medical front.
In “GTS3.0”, we will focus on research and development of new drugs and treatments for pediatric, rare and intractable diseases. We understand realizing this goal is not an easy step. However, we will drive forward tenaciously our R&D activities this year to create new solution for patients suffering from those diseases so that they could play an active role in the society in the future.
We would appreciate your continued support!
Gene Techno Science
President ＆ CEO